<PAGE> 1
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12B-25
<TABLE>
<S> <C>
------------------------
NOTIFICATION OF LATE FILING SEC FILE NUMBER
0-18976
------------------------
------------------------
CUSIP NUMBER
151186103
------------------------
(Check One)
[X] Form 10-K and Form 10-KSB [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q and Form 10-QSB
[ ] Form N-SAR
For Period Ended: March 31, 1998
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ___________________________
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
PART I --REGISTRANT INFORMATION
CELTRIX PHARMACEUTICALS, INC.
- -------------------------------------------------------------------------------------------------------
Full Name of Registrant
N/A
- -------------------------------------------------------------------------------------------------------
Former Name if Applicable
3055 PATRICK HENRY DRIVE
- -------------------------------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
SANTA CLARA, CA 95054-1815
- -------------------------------------------------------------------------------------------------------
City, State and Zip Code
</TABLE>
<PAGE> 2
PART II - RULES 12B-25(B) AND (C)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
[X] (a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or
expense;
[X] (b) The subject annual report, semi-annual report, transition report
on Form 10 K, Form 20-F, 11-K, Form N-SAR, or portion thereof
will be filed on or before the fifteenth calendar day following
the prescribed due date; or the subject quarterly report or
transition report on Form 10-Q, or portion thereof will be filed
on or before the fifth calendar day following the prescribed due
date; and
[ ] (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reasons why the Form 10-K and Form 10-KSB,
20F, 11-K, 10-Q and Form 10-QSB, N-SAR, or the transition report or portion
thereof, could not be filed within the prescribed period. (Attach Extra Sheets
if Needed)
Registrant was not able to file its Annual Report on Form 10-K for the
year ended March 31, 1998 because its financial audit is not complete.
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Donald D. Huffman (408) 988-2500
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter
period that the registrant was required to file such report(s) been
filed? If answer is no, identify report(s). [X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected
by the earnings statements to be included in the subject report or
portion thereof? [ ] Yes [X] No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
-2-
<PAGE> 3
CELTRIX PHARMACEUTICALS, INC.
(Name of Registrant as specified in charter)
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
<TABLE>
<S> <C>
Date: June 29, 1998 By /s/ Donald D. Huffman
------------------------------------
Donald D. Huffman
Vice President, Finance and Administration, Chief
Financial Officer and Assistant Secretary (Principal
Financial and Accounting Officer)
</TABLE>
-3-
